{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:39:15Z","timestamp":1773290355507,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":2181,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Intramural Program of the Center for Cancer Research, National Cancer Institute"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1093\/annonc\/mdt464","type":"journal-article","created":{"date-parts":[[2013,11,21]],"date-time":"2013-11-21T14:52:28Z","timestamp":1385045548000},"page":"x22-x26","source":"Crossref","is-referenced-by-count":9,"special_numbering":"S10","title":["Clinical implications of using molecular diagnostics for ovarian cancers"],"prefix":"10.1016","volume":"24","author":[{"given":"E.C.","family":"Kohn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Romano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-M.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdt464_bb0010","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1002\/cncr.26618","article-title":"Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study","volume":"118","author":"Bodurka","year":"2012","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdt464_bb0015","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1097\/PAS.0b013e31803199b0","article-title":"Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma","volume":"31","author":"Malpica","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"10.1093\/annonc\/mdt464_bb0020","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00000478-200404000-00009","article-title":"Grading ovarian serous carcinoma using a two-tier system","volume":"28","author":"Malpica","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"10.1093\/annonc\/mdt464_bb0025","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/PAP.0b013e3181b4fffa","article-title":"Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems","volume":"16","author":"Vang","year":"2009","journal-title":"Adv Anat Pathol"},{"key":"10.1093\/annonc\/mdt464_bb0030","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1371\/journal.pmed.0050232","article-title":"Ovarian carcinoma subtypes are different diseases: implications for biomarker studies","volume":"5","author":"K\u00f6bel","year":"2008","journal-title":"PLoS Med"},{"key":"10.1093\/annonc\/mdt464_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdt464_bb0040","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ygyno.2011.03.013","article-title":"A randomized phase III trial of IV carboplatin and paclitaxel x 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study","volume":"122","author":"Mannel","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdt464_bb0045","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/modpathol.2010.215","article-title":"Calculator for ovarian carcinoma subtype prediction","volume":"24","author":"Kalloger","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1093\/annonc\/mdt464_bb0050","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/path.2744","article-title":"The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas","volume":"222","author":"Kobel","year":"2010","journal-title":"J Pathol"},{"key":"10.1093\/annonc\/mdt464_bb0055","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"30","author":"Alsop","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt464_bb0060","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJM199611073351901","article-title":"Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1","volume":"335","author":"Rubin","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdt464_bb0065","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1008433","article-title":"ARID1A mutations in endometriosis-associated ovarian carcinomas","volume":"363","author":"Wiegand","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdt464_bb0070","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.humpath.2011.03.003","article-title":"Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer\u2014shifting the paradigm","volume":"42","author":"Kurman","year":"2011","journal-title":"Hum Pathol"},{"key":"10.1093\/annonc\/mdt464_bb0075","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/PAP.0b013e31827bc24d","article-title":"Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms","volume":"20","author":"Maeda","year":"2013","journal-title":"Adv Anat Pathol"},{"key":"10.1093\/annonc\/mdt464_bb0080","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/modpathol.2011.189","article-title":"Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations","volume":"25","author":"Yamamoto","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1093\/annonc\/mdt464_bb0085","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2005.01.112","article-title":"Clinical trial designs for predictive marker validation in cancer treatment trials","volume":"23","author":"Sargent","year":"2005","journal-title":"J Clin Oncol"},{"issue":"Suppl 7","key":"10.1093\/annonc\/mdt464_bb0090","doi-asserted-by":"crossref","first-page":"vii205","DOI":"10.1093\/annonc\/mdq375","article-title":"Proteomics as a guiding tool for more effective personalized therapy","volume":"21","author":"Lee","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdt464_bb0095","first-page":"166","article-title":"HER2-directed therapy for metastatic breast cancer","volume":"27","author":"Jelovac","year":"2013","journal-title":"Oncology (Williston Park)"},{"key":"10.1093\/annonc\/mdt464_bb0100","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1056\/NEJMoa071167","article-title":"HER2 and response to paclitaxel in node-positive breast cancer","volume":"357","author":"Hayes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdt464_bb0105","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa054504","article-title":"HER2 and responsiveness of breast cancer to adjuvant chemotherapy","volume":"354","author":"Pritchard","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdt464_bb0110","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1186\/1471-2407-9-433","article-title":"HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy","volume":"9","author":"McAlpine","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1093\/annonc\/mdt464_bb0115","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/path.4088","article-title":"Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas","volume":"229","author":"Anglesio","year":"2013","journal-title":"J Pathol"},{"key":"10.1093\/annonc\/mdt464_bb0120","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1200\/JCO.2010.33.3906","article-title":"Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma","volume":"29","author":"Yatabe","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt464_bb0125","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2353\/ajpath.2010.100212","article-title":"BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas","volume":"177","author":"Wong","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1093\/annonc\/mdt464_bb0130","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/cncr.27782","article-title":"BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer","volume":"119","author":"Grisham","year":"2013","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdt464_bb0135","doi-asserted-by":"crossref","first-page":"6915","DOI":"10.1158\/0008-5472.CAN-04-2067","article-title":"Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors","volume":"64","author":"Ho","year":"2004","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdt464_bb0140","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/jnci\/95.6.484","article-title":"Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma","volume":"95","author":"Singer","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdt464_bb0145","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ygyno.2007.11.013","article-title":"Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum","volume":"108","author":"Schmeler","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdt464_bb0150","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.ygyno.2011.02.017","article-title":"Low-grade serous primary peritoneal carcinoma","volume":"121","author":"Schmeler","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdt464_bb0155","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(12)70572-7","article-title":"Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study","volume":"14","author":"Farley","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdt464_bb0160","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/cncr.27833","article-title":"Ovarian cancer: making its own rules-again","volume":"119","author":"Kohn","year":"2013","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdt464_bb0165","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.2011.1456","article-title":"Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer","volume":"306","author":"Yang","year":"2011","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdt464_bb0170","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdt464_bb0175","doi-asserted-by":"crossref","first-page":"18032","DOI":"10.1073\/pnas.1115052108","article-title":"Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing","volume":"108","author":"Walsh","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdt464_bb0180","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","article-title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study","volume":"12","author":"Gelmon","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdt464_bb0185","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdt464_bb0190","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/jama.295.12.1379","article-title":"Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer","volume":"295","author":"Walsh","year":"2006","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdt464_bb0195","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nrc1457","article-title":"Hallmarks of \u2018BRCAness' in sporadic cancers","volume":"4","author":"Turner","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1093\/annonc\/mdt464_bb0200","doi-asserted-by":"crossref","first-page":"e15498","DOI":"10.1371\/journal.pone.0015498","article-title":"Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer","volume":"5","author":"Etemadmoghadam","year":"2010","journal-title":"PLoS One"},{"key":"10.1093\/annonc\/mdt464_bb0205","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1158\/1078-0432.CCR-08-1564","article-title":"Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas","volume":"15","author":"Etemadmoghadam","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdt464_bb0210","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1002\/cncr.24987","article-title":"Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer","volume":"116","author":"Nakayama","year":"2010","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdt464_bb0215","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc2946","article-title":"The genesis and evolution of high-grade serous ovarian cancer","volume":"10","author":"Bowtell","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1093\/annonc\/mdt464_bb0220","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ygyno.2012.12.007","article-title":"53BP1 expression in sporadic and inherited ovarian carcinoma: relationship to genetic status and clinical outcomes","volume":"128","author":"Pennington","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdt464_bb0225","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1073\/pnas.1013715108","article-title":"Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells","volume":"108","author":"Patel","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdt464_bb0230","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/nrg2159","article-title":"Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins","volume":"8","author":"Wang","year":"2007","journal-title":"Nat Rev Genet"},{"key":"10.1093\/annonc\/mdt464_bb0235","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1124\/pr.54.3.375","article-title":"The therapeutic potential of poly(ADP-ribose) polymerase inhibitors","volume":"54","author":"Virag","year":"2002","journal-title":"Pharmacol Rev"},{"key":"10.1093\/annonc\/mdt464_bb0240","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/AOG.0b013e3181c2d294","article-title":"High poly(adenosine diphosphate-ribose) polymerase expression and poor survival in advanced-stage serous ovarian cancer","volume":"115","author":"Barnett","year":"2010","journal-title":"Obstet Gynecol"},{"key":"10.1093\/annonc\/mdt464_bb0245","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/j.ygyno.2013.04.083","article-title":"Phase I\/Ib study of the PARP inhibitor (PARPi) olaparib (O\/AZD2281) in combination with carboplatin (C) in ovarian cancer (OvCa) patients with BRCA1\/2 mutations (OvCaMUT+) and high grade serous OvCa (HGSOC) with low genetic risk (NCT00647062)","volume":"130","author":"Lee","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdt464_bb0250","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1535-6108(02)00044-2","article-title":"The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma","volume":"1","author":"Maranchie","year":"2002","journal-title":"Cancer Cell"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419373867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419373867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/24\/suppl_10\/x22\/6674132\/mdt464.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T05:18:24Z","timestamp":1716182304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419373867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":49,"alternative-id":["S0923753419373867"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdt464","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}